La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Cansortium Résultats passés
Passé contrôle des critères 0/6
Cansortium has been growing earnings at an average annual rate of 15.3%, while the Pharmaceuticals industry saw earnings growing at 48.2% annually. Revenues have been growing at an average rate of 25.9% per year.
Informations clés
15.3%
Taux de croissance des bénéfices
25.6%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 23.1% |
| Taux de croissance des recettes | 25.9% |
| Rendement des fonds propres | -230.1% |
| Marge nette | -12.8% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Cansortium Inc.'s (CSE:TIUM.U) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 21
Slammed 32% Cansortium Inc. (CSE:TIUM.U) Screens Well Here But There Might Be A Catch
Jul 11Cansortium Inc.'s (CSE:TIUM.U) Shares Not Telling The Full Story
Jan 15Is Cansortium (CSE:TIUM.U) Using Too Much Debt?
Nov 30Is Cansortium (CSE:TIUM.U) Using Debt Sensibly?
Sep 01Cansortium Inc. (CSE:TIUM.U) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough
Jul 28An Intrinsic Calculation For Cansortium Inc. (CSE:TIUM.U) Suggests It's 26% Undervalued
Mar 08Does Cansortium (CSE:TIUM.U) Have A Healthy Balance Sheet?
Jan 09Here's Why Cansortium (CSE:TIUM.U) Has A Meaningful Debt Burden
Sep 09Ventilation des recettes et des dépenses
Comment Cansortium gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 103 | -13 | 36 | 0 |
| 31 Mar 24 | 100 | -20 | 34 | 0 |
| 31 Dec 23 | 97 | -23 | 31 | 0 |
| 30 Sep 23 | 95 | -36 | 29 | 0 |
| 30 Jun 23 | 92 | -36 | 28 | 0 |
| 31 Mar 23 | 90 | -34 | 26 | 0 |
| 31 Dec 22 | 88 | -37 | 26 | 0 |
| 30 Sep 22 | 83 | -15 | 27 | 0 |
| 30 Jun 22 | 76 | -2 | 27 | 0 |
| 31 Mar 22 | 70 | -24 | 27 | 0 |
| 31 Dec 21 | 65 | -19 | 30 | 0 |
| 30 Sep 21 | 62 | -31 | 32 | 0 |
| 30 Jun 21 | 61 | -47 | 33 | 0 |
| 31 Mar 21 | 57 | -28 | 35 | 0 |
| 31 Dec 20 | 52 | -37 | 32 | 0 |
| 30 Sep 20 | 47 | -48 | 35 | 0 |
| 30 Jun 20 | 40 | -51 | 35 | 0 |
| 31 Mar 20 | 33 | -51 | 35 | 0 |
| 31 Dec 19 | 29 | -53 | 41 | 0 |
| 30 Sep 19 | 24 | -54 | 41 | 0 |
| 30 Jun 19 | 19 | -13 | 39 | 0 |
| 31 Mar 19 | 14 | -9 | 33 | 0 |
| 31 Dec 18 | 8 | 0 | 21 | 0 |
| 30 Sep 18 | 3 | 16 | 14 | 0 |
| 30 Jun 18 | 0 | -15 | 9 | 0 |
| 31 Mar 18 | 0 | -16 | 8 | 0 |
| 31 Dec 17 | 0 | -10 | 8 | 0 |
Des revenus de qualité: TIUM.U is currently unprofitable.
Augmentation de la marge bénéficiaire: TIUM.U is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: TIUM.U is unprofitable, but has reduced losses over the past 5 years at a rate of 15.3% per year.
Accélération de la croissance: Unable to compare TIUM.U's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: TIUM.U is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Rendement des fonds propres
ROE élevé: TIUM.U has a negative Return on Equity (-230.12%), as it is currently unprofitable.